PSMA-ALB-56 

PSMA-ALB-56 is a PSMA-targeting radioligand designed by combining the glutamate-urea PSMA-binding entity and an albumin binder^[1].

PSMA-ALB-56 accumulates much faster in tumor tissues and is more efficiently cleared from the blood and background tissues, which results in excellent tumor-to-background contrast already 4 hours after injection. PSMA-ALB-56 increases median survival in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1330.52

C₆₆H₉₅N₁₁O₁₈

2306049-48-7

Solid

White to off-white

O=C([C@H]1CC[C@@H](CC1)CNC([C@H](CCCCNC(CCCC2=CC=C(C=C2)C)=O)NC(CN3CCN(CCN(CCN(CC3)CC(O)=O)CC(O)=O)CC(O)=O)=O)=O)N[C@H](C(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)CC4=CC5=C(C=CC=C5)C=C4

Room temperature in continental US; may vary elsewhere.

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Umbricht CA, et al. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy. Mol Pharm. 2018;15(6):2297-2306.  [Content Brief]